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Abstract
Recent research implicates soluble aggregated forms of a-synuclein as neurotoxic species with a central role in the
pathogenesis of Parkinson’s disease and related disorders. The pathway by which a-synuclein aggregates is believed to
follow a step-wise pattern, in which dimers and smaller oligomers are initially formed. Here, we used H4 neuroglioma cells
expressing a-synuclein fused to hemi:GFP constructs to study the effects of a-synuclein monoclonal antibodies on the early
stages of aggregation, as quantified by Bimolecular Fluorescence Complementation assay. Widefield and confocal
microscopy revealed that cells treated for 48 h with monoclonal antibodies internalized antibodies to various degrees. C-
terminal and oligomer-selective a-synuclein antibodies reduced the extent of a-synuclein dimerization/oligomerization, as
indicated by decreased GFP fluorescence signal. Furthermore, ELISA measurements on lysates and conditioned media from
antibody treated cells displayed lower a-synuclein levels compared to untreated cells, suggesting increased protein
turnover. Taken together, our results propose that extracellular administration of monoclonal antibodies can modify or
inhibit early steps in the aggregation process of a-synuclein, thus providing further support for passive immunization
against diseases with a-synuclein pathology.
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Introduction
Parkinson’s disease, dementia with Lewy bodies and multiple
system atrophy are neurodegenerative disorders characterized by
the loss of neurons in the brain along with the presence of large
intracellular protein inclusions known as Lewy bodies [1,2]. The
major protein component of Lewy bodies is a-synuclein, a 140
amino acid long protein with a partially unfolded structure [3].
Although a-synuclein has a largely unknown function, recent
findings suggest it to be involved in neurotransmitter regulation.
For example, a-synuclein may regulate the reuptake of dopamine
into striatum of transgenic mice [4] or be more generally involved
in synaptic release by promoting SNARE complex assembly [5].
The aggregation cascade of a-synuclein is believed to begin with
the formation of dimers and smaller oligomers before the
appearance of larger oligomers or protofibrils [6]. Such soluble
pre-aggregated species have been demonstrated to have toxic
properties and may thus play a central role in the pathogenesis
[7,8,9,10,11]. In addition, the disease associated mutations in the
gene encoding for a-synuclein have been found to increase the
formation of oligomers/protofibrils, further supporting the path-
ogenic significance of such species [12,13,14].
Alpha-synuclein aggregation has been widely studied in cell
culture models. By overexpressing a-synuclein, intracellular
inclusions can be induced in a wide range of cell types via various
aggregation-promoting conditions [15,16]. Early stages of protein
aggregation can be assessed with protein-fragment complementa-
tion techniques [17]. One such method, the bimolecular
fluorescence complementation (BiFC) assay, has previously been
adopted for the study of a-synuclein aggregation [7]. By fusing
DNA encoding either the C-terminal or N-terminal halves of GFP
to the entire a-synuclein sequence, two forms of a-synuclein
hemi:GFP constructs are generated. Upon double transfection of
cells with these constructs, fluorescence arises only when the
fragments are brought together, i.e. after dimerization/oligomer-
ization of a-synuclein.
In the last decade, immunotherapy has emerged as a promising
tool to target and clear protein pathology in neurodegenerative
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precursor protein (AbPP) mice, using fibrils of the amyloid beta
peptide (Ab), a distinct reduction of Ab pathology could be seen
[18]. In addition, Ab immunization has been found to alleviate
memory impairment in transgenic animal models [19]. Instead of
vaccination in Alzheimer’s disease, focus has now been set on
passive treatment with antibodies against Ab. Such an approach
has proven to be equally efficient in both cell and animal models
and is likely to be a safer therapeutic option, as T-cell mediated
side effects can be avoided [20,21].
Immunotherapy has now also begun to be evaluated as an
approach to treat a-synuclein pathology. In one study, active
immunization with a-synuclein on transgenic mice showed that
the pathology was less pronounced in vaccinated mice as
compared to placebo [22]. As for passive immunotherapy against
a-synuclein pathology, a recent study described reduced behav-
ioral deficit as well as decreased accumulation of a-synuclein
aggregates in an a-synuclein transgenic mouse model [23].
Here, we explored the use of monoclonal a-synuclein antibodies
to target dimerization/oligomerization on a cell culture model,
using BiFC.
Materials and Methods
Alpha-synuclein constructs
The G-N-155-a-syn and a-syn-G-156-C constructs used for the
BiFC assay were generated as described earlier [7]. For all
transfection experiments, an empty pcDNA3.1 expression vector
(Invitrogen, Carlsbad, CA) was used as control.
Cell culture
Human H4 neuroglioma cells were a kind gift of Dr. Bradley T.
Hyman (Massachusetts General Hospital, Charlestown, MA).
Cells were cultured at 37uC and 5% CO2 in OPTI-MEM
(Invitrogen) and supplemented with 10% fetal bovine serum (FBS)
(Invitrogen) and 4 mM Glutamine (Invitrogen).
Antibodies
The following a-synuclein monoclonal antibodies (mAb) were
used for cell culture treatment: mAb211 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), mAb5C2 (Santa Cruz Biotechnology) and
the oligomer-selective antibody mAb49/G (BioArctic Neurosci-
ence, Stockholm, Sweden). The monoclonal GAPDH antibody
9484 (Abcam, Cambridge, UK) was used as a negative treatment
control. All antibodies used for cellular treatment were diluted in
TBS to reach a final concentration of 1 mg/ml in the extracellular
media. For the sandwich ELISA, the Syn-1 (BD Biosciences,
Franklin Lakes, NJ) and FL-140 (Santa Cruz Biotechnology) a-
synuclein antibodies were used for capture and detection,
respectively. For immunocytochemistry experiments, anti-mouse
Cy3 or Alexa594 conjugated secondary antibodies (Invitrogen)
were used.
Generation of the oligomer-selective a-synuclein
antibody mAb49/G
Balb/c mice (The Jackson Laboratory, Bar Harbor, Maine)
were immunized with 4-hydroxy-2-nonenal (HNE) stabilized a-
synuclein oligomers [11] diluted 1:1 (v:v) with Freund’s adjuvant.
After repeated boosts, immunized mice with high serum titers
were sacrificed for isolation of spleen cells. Next, the spleen cells
were fused with SP2/0 myeloma cells. Hybridomas were screened
for anti-a-synuclein reactivity with ELISA and positive clones
underwent at least two rounds of limiting dilution assay to ensure
monoclonality. The IsoStrip kit (Roche Diagnostics, Basel,
Switzerland) was used to determine isotype and subclass of the
antibody. The mAb49/G IgG1 antibody was then purified from
the conditioned media with affinity chromatography using Protein
G-Sepharose (GE Healthcare, Uppsala, Sweden). All experiments
involving animals were approved by the local ethical committee
(Stockholms Norra djurfo ¨rso ¨ksetiska na ¨mnd, decision numbers
N417/08; 2009-01-15).
Inhibition ELISA
An inhibition ELISA assay was performed as described
previously using a-synuclein monomer coated plates. As compet-
itors, a-synuclein monomers and HNE stabilized a-synuclein
oligomers were used [24].
Transfection and addition of monoclonal antibodies
Prior to the day of transfection, cells were seeded onto 35 mm
poly-D-lysine coated culture plates (MatTek Cultureware, Ash-
land, MA) at a density of 1,5610
5 cells/plate. Transfection of H4
cells were carried out with a 1:5 ratio (mg DNA:ml FuGENE), using
the FuGENE 6 Transfection reagent (Roche Diagnostics). In brief,
the culture medium was replaced with medium containing 1%
FBS, transfected and left to incubate at 37uC for 24 h. For
bioimaging, to ensure optimal reconstitution of the two GFP
fragments, cells were incubated over night at 30uC [7,25].
Moreover, cells were treated or untreated at time zero of
transfection with either of the mAb211, mAb5C2 or mAb49/G
a-synuclein antibodies or with the mAb9484 GAPDH antibody
for 48 h at a final antibody concentration of 1 mg/ml.
Immunocytochemistry
Cells were washed with PBS and subsequently fixed for 10 min
in 4% paraformaldehyde (PFA). After permeabilization for 20 min
in 0.1% Triton X-100 at room temperature, the cells were blocked
with 1.5% normal goat serum (NGS) (Invitrogen) for 2 h. After
washing with PBS, cells were incubated with a Cy3 conjugated
secondary antibody (Invitrogen) (1:5000 in 1.5% NGS) for 1 h.
Finally, cells were stained with DAPI (Invitrogen) (1:20000 in
1.5% NGS) for 10 min.
Control cells were stained using the mouse monoclonal a-
synuclein antibodies mAb49/G (BioArctic Neuroscience),
mAb211 (Santa Cruz Biotechnology) and mAb5C2 (Santa Cruz
Biotechnology) (1:500 in 1.5% NGS) for 2 h. Next, cells were
probed with the Alexa-Fluor 594 conjugated secondary antibody
(Invitrogen) (1:5000 in 1.5% NGS) for 1 h. Finally, cells were
stained with DAPI (Invitrogen) (1:20000 in 1.5% NGS) for
10 min. All incubations were performed at room temperature.
To control for unspecific binding of the secondary antibodies,
cells were treated only with a mouse secondary antibody and
compared to buffer treated controls. To control for passive uptake
of the a-synuclein antibodies as an effect of DNA-transfection,
additional experiments in which the antibodies were added with
and without simultaneous administration of FuGENE 6 were
carried out.
Cells were analyzed with confocal microscopy using a LSM 510
META instrument (Carl Zeiss Microimaging) where single plane
and z-slice images of antibody internalization were obtained.
Fixing cells and fluorescence microscopy
At the end of the treatment, cells were washed with PBS and
subsequently fixed for 10 min in 4% paraformaldehyde (PFA). To
study GFP fluorescence the cells were analyzed using an Axiovert
200 M widefield fluorescence microscope (Carl Zeiss Microima-
ging GmbH, Jena, Germany). The cells were observed using an
Antibodies Reduce Alpha-Synuclein Oligomerization
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random sites in the well for each condition were observed using a
20X objective.
Quantification of fluorescence intensity and image
processing
For quantification of pixel intensities, the ImageJ (NIH,
Bethesda, MD) software was used. The GFP fluorescence was
converted to average pixel intensities for each condition. The
intensities for each captured frame are presented as fold increase
in fluorescence over vector transfected controls. A standard
threshold for the highest exposure of positive pixels was set for
the green channel by using a-synuclein–BiFC expressing cells
without antibody treatment (-mAb). To test for statistically
significant differences, groups were subjected to one-way
ANOVA. Probability values ,0.05 were considered significant
using a two-tailed confidence interval.
Preparation of conditioned media and cell lysates
Forty-eight hours after transfection and antibody treatment, the
conditioned media was recovered and centrifuged at 2150 x g at
4uC for 10 min. To concentrate the samples, the conditioned
media was freeze-dried and re-dissolved in CellyticM (Sigma-
Aldrich, St. Louis, MO) lysis buffer supplemented with protease
inhibitor cocktail (Roche Diagnostics). The cells were washed with
PBS, lysed with CellyticM (Sigma-Aldrich) and supplemented with
a protease inhibitor cocktail (Roche Diagnostics). The lysate was
collected and centrifuged at 4uC for 10 min and 20800 x g.
Protein concentrations in conditioned media and lysates were
determined with the BCA Protein Assay Reagent (Thermo Fisher
Scientific, Rockford, IL).
Sandwich ELISA
A 96-well high binding plate polystyrene microtiter plate
(Corning) was coated with 200 ng/well of Syn-1 (BD Biosciences)
in PBS and incubated at 4uC over night. The solution was
removed from each well and the cells were blocked with 1% BSA/
0.15% Kathon for 1 h at room temperature. The samples,
including a standard series of recombinant a-synuclein diluted in
1% BSA, 0.05% Tween and 0.15% Kathon, were added to the
wells and incubated with shaking at room temperature for 2 h.
After washing, the FL-140 polyclonal a-synuclein antibody (Santa
Cruz Biotechnology) was diluted to 1 mg/ml and added to the
wells, followed by shaking at room temperature for 1 h. Next, the
wells were washed and an anti-rabbit horse radish peroxidase
(HRP) conjugated detection antibody (Pierce, Rockford, IL, USA)
was added at a final concentration of 0.4 mg/ml. After a further
incubation for 1 h, the wells were washed and the K-blue aqueous
substrate (TMB) was used as substrate for HRP. Before
measurement, the reaction was stopped using 1 M H2SO4. The
plate was measured using a SpectraMAX 190 (Molecular Devices,
Palo Alto, CA) spectrophotometer at 450 nm. The data for each
sample was calculated as the means of three separate wells.
Results
Characterization of mAb49/G
Immunization of mice with HNE stabilized a-synuclein
oligomers resulted in several monoclonal antibodies, among which
mAb49/G was chosen for this study. By inhibition ELISA, the
binding of mAb49/G to an HNE stabilized a-synuclein oligomer
coated plate was inhibited by addition of serially diluted a-
synuclein species. When adding a-synuclein oligomers, the IC50
levels were in the low nanomolar range (0.7 nM) whereas the
addition of at least 80 nM a-synuclein monomers were needed to
quench the same signal, indicating a strong selectivity of mAb49/
G for oligomeric a-synuclein (Fig. 1).
Cellular internalization of the a-synuclein antibodies
Antibody uptake was studied with immunocytochemistry
followed by widefield and confocal microscopy. After 48 h of
transfection with the two a-synuclein hemi:GFP constructs, GFP
fluorescence was detected with widefield microscopy indicating
dimerization/oligomerization of a-synuclein (Fig. 2A). In parallel
experiments, cells transfected with the two a-synuclein hemi:GFP
constructs and immediately treated with the mAb49/G, mAb211
and mAb5C2 antibodies for 48 h, displayed occasional small
punctae of a-synuclein in the cell soma after immunostaining with
secondary antibodies (Fig. 2D, E and F, arrows). Interestingly,
these punctae partly co-occurred with GFP-positive signals,
indicating internalization of the extracellularly added a-synuclein
antibodies mAb49/G and mAb211 (Fig. 2D, E, arrows). However,
by examining inclusion staining for the 5C2 antibody, cells
exhibited red signals with no co-occurring GFP-fluorescence
indicating binding to monomeric forms of the a-synuclein
hemi:GFP for this particular antibody (Fig. 2F, arrows).
Figure 1. Characterization of mAb49/G by inhibition ELISA. Binding of mAb49/G to a-synuclein monomers (%)o ra-synuclein oligomers (N)
was analyzed on HNE stabilized a-synuclein oligomer coated plates. On the x-axis, the molar concentration of a-synuclein is displayed. The IC50
values are calculated as the concentration of either a-synuclein monomers or a-synuclein oligomers needed to quench half of the signal in the ELISA.
Note that, due to uncertainties concerning the size of the a-synuclein oligomers used in this assay, the concentration in pM for both species is based
on the molecular weight of one a-synuclein monomer. These data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0027230.g001
Antibodies Reduce Alpha-Synuclein Oligomerization
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e27230To confirm antibody uptake, cells were also analyzed by confocal
microscopy. All antibodies were then found to get internalized by
obtaining z-slice images, but the intracellular presence of mAb49/G
and mAb211 was especially pronounced (Fig. 3A, B and C, arrows).
Moreover, the antibodies labeled several small inclusions throughout
thecellsomabutwerenotfoundtostainthenucleus(Fig.3A–C).For
comparison, cells were subjected to ordinary immunocytochemistry
using the mAb49/G, mAb211 and 5C2 as primary antibodies
(Fig. 3D–F). Indeed, a similar pattern of immunofluorescence
staining was detected in those cells confirming antibody localization
to small inclusions of a-synuclein in the cell soma (Fig. 3A–C).
To control for passive uptake of the antibodies as a result of
DNA transfection, we performed experiments in which the
antibodies were incubated with or without the presence of
FuGENE 6. However, we could not see any difference in antibody
uptake between these two experimental conditions, thus indicating
that the antibody uptake was not dependent on the presence of cell
permeabilization reagents (data not shown).
Reduced oligomerization after treatment with C-terminal
specific and oligomer selective a-synuclein antibodies
H4 neuroglioma cells were transfected with the two a-synuclein
hemi:GFP constructs. Forty eight hours after transfection, GFP
fluorescence could be detected in the cell soma and the nucleus in
approximately 50% of the cells, indicating a-synuclein dimeriza-
tion/oligomerization (Fig. 4A). The fluorescence in a-synuclein
hemi:GFP transfected cells corresponded to a robust increase in
fluorescence (2.7-fold over expression to vector controls).
In parallel experiments, a-synuclein antibodies were added to
the cell media immediately after transfection. Addition of the a-
synuclein C-terminal antibodies mAb49/G and mAb211 reduced
the GFP fluorescence significantly (1.4- and 1.5-fold over
Figure 2. Immunocytochemistry with anti-mouse secondary antibodies (Cy3) displays internalization of the a-synuclein
monoclonal antibodies (+mAb). Forty-eight hours after transfection with the two a-synuclein hemi:GFP constructs, cells displayed GFP
fluorescence in the whole cell soma (green) (Fig. A). Cells transfected with the constructs and treated with the a-synuclein antibodies mAb49/G and
mAb211 displayed less diffuse GFP fluorescence but more localized GFP-punctae (Fig. D, E, arrows). These signals occasionally co-occurred with
signals from an anti-mouse secondary antibody, indicating internalization (yellow) of the treatment antibodies (Fig. D, E, arrows). Cells treated with
the mAb5C2 antibody only displayed diffuse GFP-fluorescence in the whole cell soma (Fig. F). After staining with an anti-mouse secondary antibody
red punctae could be detected in the cells indicating no co-occurrence with GFP (Fig. F, arrows). The blue signal represents DAPI nuclear staining (40x
magnification. Scale bar 20 mm).
doi:10.1371/journal.pone.0027230.g002
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(Fig. 4D, E and G). With the a-synuclein mid-region antibody
mAb5C2, raised against the non-Ab component (NAC) region,
there was no reduction (2.5-fold over expression to vector controls)
of GFP fluorescence (Fig. 4C and G).
Thus, treatment with C-terminal a-synuclein antibodies resulted
in decreased formation of a-synuclein dimers/oligomers (Fig. 4D
and E), whereas treatment with the mid-region antibody mAb5C2
did not seem to affect the extent of a-synuclein oligomerization.
To ensure that the effects were specific to the a-synuclein
antibodies, the monoclonal GAPDH antibody mAb9484 was
added in parallel (Fig. 4C). No apparent decrease (2.6-fold over
expression to vector controls) of GFP fluorescence was seen with
this antibody, thus indicating that a-synuclein oligomerization was
not affected by an irrelevant monoclonal antibody (Fig. 4C and G).
Decreased intra and extracellular levels of a-synuclein
from antibody treated cells
A sandwich ELISA was used to measure a-synuclein levels in
lysate and conditioned media from the same cells that were
analyzed for BiFC. In lysate from BiFC expressing cells (with no
mAb added), a-synuclein levels were calculated to 5.6 ng/ml
(Fig. 5A). In comparison, levels of a-synuclein in lysates treated
with a-synuclein antibodies for 48 h were 2.8 ng/ml with mAb49/
G treatment (*p,0.04), 3.9 ng/ml with mAb211 (*p,0.05) and
3.3 ng/ml with mAb5C2 (*p,0.05), indicating reduced a-
synuclein levels in cell lysates with antibody treatment (Fig. 5A).
In conditioned media from untreated cells, a-synuclein levels
were calculated to be 6.9 ng/ml (Fig. 5B). In media from cells
treated with a-synuclein antibodies for 48 h, a-synuclein levels
were 3.2 ng/ml after treatment with mAb49/G (*p,0.05),
2.2 ng/ml with mAb211 (*p,0.05) and 2.3 ng/ml (*p,0.05)
with mAb5C2 (Fig. 5B).
Discussion
The use of immunotherapy to prevent or clear abnormal
protein aggregates has emerged as a promising tool to treat
neurodegenerative diseases. Also, disorders with aggregated a-
synuclein may be targeted with immunotherapy and active
immunization in transgenic mice has indeed been shown to
reduce the accumulation of a-synuclein in the brain [22].
Although in that study it was proposed that immunization resulted
in degradation of a-synuclein via the lysosomal pathway, it is still
largely unknown by which mechanisms intraneuronal a-synuclein
aggregates can be cleared [22].
There is an ongoing debate whether extracellularly adminis-
tered antibodies can enter the cell and affect intracellular
pathology. Indeed, antibodies utilized in cancer research have
been shown to effectively bind to its target after cell internalization
[26]. In addition, more recent work showed that antibodies
directed against AbPP can maintain its structure and remain
associated with its target after internalization [20]. In the present
study we could detect a-synuclein antibodies within the cells after
48 h (Fig. 3D, E and F) of incubation and find that they co-
occurred with the a-synuclein dimers/oligomers (Fig. 2D and 2E).
Furthermore, our control experiments suggested that the presence
of permeabilization reagents did not affect antibody internaliza-
tion, thus indicating that the antibody uptake was not an effect of
DNA transfection (data not shown).
Although our study indicates that a-synuclein can be targeted
intracellularly, aggregated soluble species may also be possible to
target in the extracellular space. Indeed, several recent studies on
cells and transgenic mice have indicated cell-to-cell propagation of
a-synuclein pathology [8,16,27]. In addition, neuropathological
analyses of Parkinson’s disease brains that had been transplanted
with fetal mesencephalic dopaminergic neurons displayed Lewy
bodies in the grafted cells, suggesting a similar propagation
mechanism in the human brain [28].
Our findings demonstrate that extracellularly added a-synuclein
antibodies reduced a-synuclein dimerization/oligomerization in
living cells. Previously, in vitro studies have shown that a-synuclein
aggregation can be decreased by expressing single chain fragments,
i.e. intrabodies, targeting the C-terminus of a-synuclein [29].
We found that both the oligomer-selective antibody mAb49/G
and the mAb211 antibody, raised against the C-terminal part of
Figure 3. Confocal microscopy showing internalization of the a-synuclein antibodies. Forty-eight hours after addition of the mAb49/G,
mAb211 and mAb5C2 a-synuclein antibodies, red punctate structures were detected within the cells after staining with anti-mouse secondary
antibodies (Fig A, B and C, arrows). For comparison, immunocytochemistry was carried out using mAb49/G, mAb211 and mAb5C2 as primary
antibodies (Fig. D,E and F). The blue signal represents DAPI nuclear staining (63x magnification. Scale bar 20 mm).
doi:10.1371/journal.pone.0027230.g003
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synuclein dimerization/oligomerization (Fig. 4D and 4E). On
the contrary, the mid-region antibody mAb5C2 did not signifi-
cantly reduce the degree of dimer/oligomer formation. As some of
the treated cells appeared to be somewhat smaller in size
compared to untreated cells (-mAb) (Fig. 2 and 4), we also applied
brightfield microscopy to better delineate the cell borders. By
doing so, we found that there was no apparent difference in cell
size between antibody treated and untreated cells (data not
shown).
The inhibiting effect on oligomerization by mAb49/G was
somewhat expected as we believe that this antibody recognizes an
epitope exclusively present in the oligomeric structure of a-
synuclein. Moreover, the efficient prevention with the C-terminal
a-synuclein antibodywasalsonot entirely surprising. We and others
have described that oligomers and fibrils of a-synuclein expose C-
terminal epitopes [11,30] and a-synuclein antibodies directed
against such epitopes are more efficient in clearing a-synuclein
pathology in transgenic mice [23]. Along the same lines, the lack of
effectonloweringdimer/oligomerlevelsforthe5C2antibodyinthe
current study could be explained by the fact that its hydrophobic
NAC-region epitope (61–95) is hidden in the oligomeric core [31].
To further investigate antibody effects on a-synuclein oligo-
merization, we utilized ELISA to measure levels of a-synuclein in
cell lysate and conditioned media from wells under the various
experimental conditions. In previous studies, passive administra-
tion of Ab and a-synuclein antibodies to cell and animal models
have indicated antibody-directed protein clearance via the
endosomal/lysosomal pathway [20,23] In agreement with these
findings, we showed that the levels of a-synuclein were decreased
both in cell lysate and conditioned media after antibody treatment,
pointing to an increased degradation of the targeted proteins
(Fig. 5A and 5B). Possibly, the effects seen in our and the previous
studies may be explained by antibody uptake via particular
receptors. For example, the IgG-receptor tripartite motif-contain-
ing 21 (TRIM21) was shown to mediate antibody internalization
followed by transferring of the antibody-antigen complex to the
proteasome for degradation [32].
The finding that the NAC-specific 5C2 antibody influenced a-
synuclein levels in both cell lysate and conditioned media without
affecting oligomer formation is intriguing (Fig. 4F, 5A and 5B).
Presumably, the 5C2 antibody fails to affect dimerization/
oligomerization of a-synuclein but can bind to the monomeric
a-synuclein hemi:GFP in which the NAC region is exposed.
Figure 4. Alpha-synuclein dimerization/oligomerization, as shown by GFP fluorescence reconstitution. Forty eight hours after double
transfection with the two a-synuclein hemi:GFP constructs, the H4 cells exhibited robust GFP fluorescence (2.7-fold over expression to vector
controls) throughout the cell soma and nucleus (A and G). When cells were treated (+mAb) with the a-synuclein C-terminal specific antibodies
mAb49/G and mAb211 the GFP fluorescence was significantly (*p,0.05, **p,0.01) reduced (1.4- and 1.5-fold over expression to vector controls
respectively) indicating less dimerization/oligomerization (Fig. D, E and G). The mAb5C2 antibody targeting the non-Ab component (NAC) region of
a-synuclein did not show any reduction (2.5-fold over expression to vector controls) of GFP fluorescence, indicating no effect on the formation of
dimers/oligomers (Fig. F and G). With the monoclonal antibody mAb9484 against GAPDH, no apparent effect (2.6-fold over expression to vector
controls) on dimerization/oligomerization could be seen (Fig. C and G). 20X magnification. Scale bar 20 mm.
doi:10.1371/journal.pone.0027230.g004
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explaining the decreased total a-synuclein levels seen in the
ELISA. However, the oligomer-selective mAb49/G and C-
terminal mAb211 antibodies would be more suitable antibody
candidates, as they are targeting pathological a-synuclein
aggregates rather than the physiological protein.
In summary, we have studied the effects of monoclonal a-
synuclein antibodies on the early stages of oligomerization in H4
cells. We could show that extracellularly administered C-terminal
and oligomer-selective a-synuclein antibodies are efficiently
internalized, have an inhibiting effect on a-synuclein oligomer
formation and facilitates protein turnover. Thus, these results
provide further support for passive immunotherapy against a-
synucleinopathies.
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